Page last updated: 2024-12-05

tetranitromethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10509
CHEMBL ID261663
CHEBI ID82372
SCHEMBL ID71873
MeSH IDM0021247

Synonyms (39)

Synonym
tetranitromethane [un1510] [oxidizer]
k1g7cku98f ,
unii-k1g7cku98f
tetan
nsc 16146
un1510
hsdb 852
einecs 208-094-7
rcra waste number p112
rcra waste no. p112
ccris 2371
nsc16146
wln: wnxnwnwnw
509-14-8
methane, tetranitro-
tetranitromethane ,
TNM ,
nci-c55947
nsc-16146
NCGC00091783-01
NCGC00091783-02
CHEMBL261663
chebi:82372 ,
NCGC00091783-03
C19300
cas-509-14-8
dtxcid201334
dtxsid5021334 ,
tox21_302834
NCGC00256516-01
tox21_202353
NCGC00259902-01
tetranitromethane [hsdb]
tetranitromethane [iarc]
tetranitromethane [mi]
SCHEMBL71873
un 1510
Q412241
tetranitromethane(technical)

Research Excerpts

Overview

Tetranitromethane (TNM) is a reagent which reacts with the tyrosine and cysteine residues of proteins.

ExcerptReferenceRelevance
"Tetranitromethane (TNM) is a reagent which reacts with the tyrosine and cysteine residues of proteins. "( Chemical modification of alpha 2-adrenoceptors. Possible role for tyrosine in the ligand binding site.
Lefkowitz, RJ; Nakata, H; Regan, JW, 1986
)
1.71

Treatment

Tetranitromethane treatment of submitochondrial particles results in marked inhibition of ATP hydrolysis, ATP-33Pi exchange, and proton conduction by the H+ -ATPase complex. Treatment led to nitration of about ten tyrosine residues per IgG molecule in both species.

ExcerptReferenceRelevance
"Tetranitromethane treatment of submitochondrial particles results in marked inhibition of ATP hydrolysis, ATP-33Pi exchange, and proton conduction by the H+ -ATPase complex."( On the mechanism of H+ translocation by mitochondrial H+ -ATPase. Studies with chemical modifier of tyrosine residues.
Guerrieri, F; Papa, S; Yagi, A; Yagi, T, 1984
)
0.99
"The tetranitromethane treatment led to nitration of about ten tyrosine residues per IgG molecule in both species, and the modification was specific for tyrosine residues."( Comparison of the role of tyrosine residues in human IgG and rabbit IgG in binding of complement subcomponent C1q.
Easterbrook-Smith, SB; McCall, MN, 1989
)
0.76
"Treatment with tetranitromethane (TNM) rapidly and irreversibly inactivates uridine phosphorylase (UPase) from E. "( Modification with tetranitromethane of an essential tyrosine residue in uridine phosphorylase from Escherichia coli.
Debabov, VG; Komissarov, AA, 1995
)
0.98
"Treatment with tetranitromethane, a reagent which nitrates tyrosine residues, abolishes cyclooxygenase activity, but this inactivation can be largely prevented by competitive cyclooxygenase inhibitors such as ibuprofen and indomethacin."( Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis.
DeWitt, DL; Kulmacz, RJ; Shimokawa, T; Smith, WL, 1990
)
0.62

Dosage Studied

ExcerptRelevanceReference
" At a dosage of 1000-fold excess over the 125I-labeled oH, all the preparations tested in this series completely inhibited the specific binding of 125I-labeled oLH to the hormone receptors in rat testis preparations."( Effect of selective nitration of ovine lutropin on the subunit association and biological activity of the hormone.
Liu, WK; Ward, DN, 1976
)
0.26
" The frequencies of the K-ras mutations were 57% (29/51) in BMP-induced lung neoplasms compared to 15% (3/20) in lung neoplasms from dosed feed control mice, and 54% (14/26) in TNM-induced lung neoplasms compared to 60% (3/5) in lung neoplasms from inhalation control mice."( Predominant K-ras codon 12 G --> A transition in chemically induced lung neoplasms in B6C3F1 mice.
Anna, CH; Devereux, TR; Dunnick, JK; Hong, HH; Kim, Y; Sills, RC; Ton, TV,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
quercetin gentiotetraside biosynthesis317
kaempferol gentiobioside biosynthesis317
flavonol glucosylation I118
myricetin gentiobioside biosynthesis316
myricetin gentiobioside biosynthesis317
superpathway of L-phenylalanine biosynthesis1665
L-phenylalanine biosynthesis I628
L-histidine degradation II522
superpathway of aromatic amino acid biosynthesis2184
superpathway of chorismate metabolism56186
quercetin gentiotetraside biosynthesis319

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency14.12540.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.33650.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency8.94120.000714.592883.7951AID1259369; AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency42.83820.001022.650876.6163AID1224838; AID1224893
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency31.62280.000214.376460.0339AID588532
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.48620.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency15.35530.001530.607315,848.9004AID1224841; AID1224842
pregnane X nuclear receptorHomo sapiens (human)Potency61.69100.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency11.17170.000229.305416,493.5996AID743069
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency48.97220.001019.414170.9645AID743094
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00140.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.80660.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency38.13240.000627.21521,122.0200AID651741; AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (398)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990260 (65.33)18.7374
1990's88 (22.11)18.2507
2000's44 (11.06)29.6817
2010's6 (1.51)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.71 (24.57)
Research Supply Index6.00 (2.92)
Research Growth Index3.93 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other397 (98.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]